Terms: = Thyroid cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Treatment
88 results:
1. thyroid dysfunction caused by exposure to environmental endocrine disruptors and the underlying mechanism: A review.
He J; Xu J; Zheng M; Pan K; Yang L; Ma L; Wang C; Yu J
Chem Biol Interact; 2024 Mar; 391():110909. PubMed ID: 38340975
[TBL] [Abstract] [Full Text] [Related]
2. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
[TBL] [Abstract] [Full Text] [Related]
3. HDAC inhibitors target IRS4 to enhance anti‑AR therapy in AR‑positive triple‑negative breast cancer.
He Y; Ma Y; Zhu Y; Zhang J; Zhao S; Zhang D; Xu D; Li Y; Tong Z; Zhao W
Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38214343
[TBL] [Abstract] [Full Text] [Related]
4. Fine-needle biopsy of thyroid nodules and the contribution of molecular analysis of BRAF and RAS mutations.
Kasko M; Grigerova M; Alemayehu A; Zavodna K; Kasko V; Podoba J
Bratisl Lek Listy; 2023; 124(12):869-872. PubMed ID: 37983279
[TBL] [Abstract] [Full Text] [Related]
5. Macrofollicular Architecture in Invasive Encapsulated Follicular Variant of Papillary thyroid Carcinoma: A Pitfall in thyroid Practice.
Yadav S; Kandasamy D; Damle N; Goel R; Chumber S; Sharma MC; Boruah M; Agarwal S
Head Neck Pathol; 2023 Dec; 17(4):899-909. PubMed ID: 37775618
[TBL] [Abstract] [Full Text] [Related]
6. Clinical Characteristics and Responses to Immune Checkpoint Inhibitors in RET-Aberrant Digestive Tract Tumours.
Yen CC; Yeh YM; Huang HY; Ting YL; Fu PA; Lin TC; Liu IT; Yen CJ
Target Oncol; 2023 Jul; 18(4):611-623. PubMed ID: 37347391
[TBL] [Abstract] [Full Text] [Related]
7. Identification of crucial genes involved in thyroid cancer development.
Kalarani IB; Sivamani G; Veerabathiran R
J Egypt Natl Canc Inst; 2023 May; 35(1):15. PubMed ID: 37211566
[TBL] [Abstract] [Full Text] [Related]
8. Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients.
Horesh A; Pollack R; Nechushtan H; Dresner-Pollak R; Neuman T
Pathol Oncol Res; 2023; 29():1610951. PubMed ID: 37139142
[No Abstract] [Full Text] [Related]
9. Blood Liquid Biopsy in an Advanced Medullary thyroid Carcinoma: A Case Study with Rearranged during Transfection Heterogeneity.
Gumà J; Peña KB; Riu F; Lucia-Gozálvez C; Vidaller A; Maldonado V; Parada D
Pathobiology; 2023; 90(4):281-288. PubMed ID: 36731433
[TBL] [Abstract] [Full Text] [Related]
10. Efficacy of Immunotherapy in Second-Line treatment of
Knetki-Wróblewska M; Tabor S; Płużański A; Lewandowska Z; Tysarowski A; Pawlik H; Kowalski DM; Krzakowski M
Curr Oncol; 2022 Dec; 30(1):462-475. PubMed ID: 36661686
[TBL] [Abstract] [Full Text] [Related]
11. Clinicopathological and Molecular Features of Secondary cancer (Metastasis) to the thyroid and Advances in Management.
Nguyen M; He G; Lam AK
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328664
[TBL] [Abstract] [Full Text] [Related]
12. DCZ0415, a small-molecule inhibitor targeting TRIP13, inhibits EMT and metastasis via inactivation of the FGFR4/STAT3 axis and the Wnt/β-catenin pathway in colorectal cancer.
Agarwal S; Afaq F; Bajpai P; Kim HG; Elkholy A; Behring M; Chandrashekar DS; Diffalha SA; Khushman M; Sugandha SP; Varambally S; Manne U
Mol Oncol; 2022 Apr; 16(8):1728-1745. PubMed ID: 35194944
[TBL] [Abstract] [Full Text] [Related]
13. Phospho-Aspirin (MDC-22) inhibits pancreatic cancer growth in patient-derived tumor xenografts and KPC mice by targeting EGFR: Enhanced efficacy in combination with irinotecan.
Rodriguez Lanzi C; Wei R; Luo D; Mackenzie GG
Neoplasia; 2022 Feb; 24(2):133-144. PubMed ID: 34968866
[TBL] [Abstract] [Full Text] [Related]
14. cancer Therapy Guided by Mutation Tests: Current Status and Perspectives.
Aleksakhina SN; Imyanitov EN
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681592
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic value of thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1.
Galland L; Le Page AL; Lecuelle J; Bibeau F; Oulkhouir Y; Derangère V; Truntzer C; Ghiringhelli F
Oncoimmunology; 2021; 10(1):1957603. PubMed ID: 34377595
[TBL] [Abstract] [Full Text] [Related]
16. Total thyroidectomy can still remain the method of choice in some Bethesda III cases.
Lukas J; Hintnausova B; Sykorova V; Syrucek M; Maly M; Duskova J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2023 Mar; 167(1):61-68. PubMed ID: 34282807
[TBL] [Abstract] [Full Text] [Related]
17. Nonclinical Safety Profile of Sotorasib, a kras
Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T
Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282
[TBL] [Abstract] [Full Text] [Related]
18. Rare germline variants in DNA repair-related genes are accountable for papillary thyroid cancer susceptibility.
Mio C; Verrienti A; Pecce V; Sponziello M; Damante G
Endocrine; 2021 Sep; 73(3):648-657. PubMed ID: 33821390
[TBL] [Abstract] [Full Text] [Related]
19. A Narrative Review of Genetic Alterations in Primary thyroid Epithelial cancer.
Romei C; Elisei R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572167
[TBL] [Abstract] [Full Text] [Related]
20. Serine 897 Phosphorylation of EPHA2 Is Involved in Signaling of Oncogenic ERK1/2 Drivers in thyroid cancer Cells.
Allocca C; Cirafici AM; Laukkanen MO; Castellone MD
Thyroid; 2021 Jan; 31(1):76-87. PubMed ID: 32762307
[No Abstract] [Full Text] [Related]
[Next]
